The IC 50 of an inhibitor varies depending on assay conditions such as substrate concentration (1), as depicted for PTC124 in Fig. 1 A of Peltz et al.'s letter (2). Steady-Glo and BrightGlo differ in luciferase substrate composition, making comparison of inhibitor potency using these commercial formulations meaningless and inconsequential to inhibitor-based stabilization of the reporter occurring intracellularly (Fig. 1 in  ref. 3). Accurate determination of the affinity of the enzymeinhibitor complex is obtained through the constant K I (1, 4), which we estimated to be Ϸ10 nM for PTC124 against FLuc (using [S]ϳK M ) (3). Further, using a classic pharmacological approach (5)-strong correlation between inhibition of isolated FLuc and potency in cell-based assays of PTC124 and analogs ( Fig. 4C in ref. 3)-we unmistakably demonstrate that increases in cell-based FLuc activity is due to PTC124 interaction with the FLuc protein.
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Peltz et al.'s inability to reproduce our findings in the cellbased FLuc assay (Fig. 1B in ref. 2) is likely due to their omission of a critical step in our stated protocol, which removes PTC124, a potent inhibitor, by wash steps prior to detection (3). This allows measurement of the true FLuc activity without the complications illustrated by Peltz et al. (Fig. 1 in   ref. 2) and supports our finding that the observed response is highly biased by FLuc inhibitory activity. Furthermore, our RLuc-based readthrough assay, which showed that PTC124 was inactive, demonstrated sufficient sensitivity to gentamicin (2-fold activation), an RLuc inhibitor (compd.4; Ϸ2.5-fold), and a transcriptional activator (Ϸ7-fold; Fig. 3, in ref. 3)-sensitivity not demonstrated in the assay conducted by Welch et al. (6) .
Thus by all standard enzymological and pharmacological measures, PTC124 potently binds to FLuc leading to increased cell-based activity via post-translational reporter stabilization.
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